Literature DB >> 1511059

Blood transfusion in marrow graft recipients.

P Pihlstedt1, T Paulin, B Sundberg, B Nilsson, O Ringdén.   

Abstract

Of 182 consecutive patients undergoing allogeneic bone marrow transplantation (BMT), the relative numbers of those who received red blood cells (RBC), platelets (PLT), and granulocytes were 82%, 96%, and 26%, respectively. The transfused patients received an average of 1.26 (SD +/- 2.0) RBC units, 9.41 (SD +/- 13.2) PLT transfusions, and 0.33 (SD +/- 1.1) granulocyte concentrates per week per 50 kg body wt. in the period starting on the day of bone marrow transplantation (BMT) up to 60 days post BMT. The total number of units per transfused patient was 7.7 (range 1-63) RBC, 55.2 (range 2-394) PLT and 6.2 (range 1-36) granulocytes in the same period. Patients with grades II-IV acute graft-versus-host disease (GVHD) needed more RBC and PLT (p less than 0.001) than patients with grades 0-I acute GVHD. Patients with late engraftment required more granulocyte and PLT transfusion than those with early engraftment (p less than 0.05). Patients with high-risk malignancy had greater need for RBC and PLT than "low-risk patients" (p less than 0.02 and p less than 0.01), respectively). Patients with major ABO-incompatible donors showed a greater need for RBC than patients with minor ABO incompatibility (p = 0.02) or ABO identical donors (p = 0.01). Patients with relatively poor estimated survival required the most RBC and PLT.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1511059     DOI: 10.1007/bf01698131

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  21 in total

1.  Marrow transplantation for aplastic anemia and leukemia--review of results and blood product support required.

Authors:  P L Weiden; S J Slichter; M Banaji
Journal:  Prog Clin Biol Res       Date:  1978

2.  Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia.

Authors:  J Gmür; J Burger; U Schanz; J Fehr; A Schaffner
Journal:  Lancet       Date:  1991-11-16       Impact factor: 79.321

Review 3.  Blood component therapy in bone marrow transplantation.

Authors:  A Brand; F H Claas; J H Falkenburg; J J van Rood; J G Eernisse
Journal:  Semin Hematol       Date:  1984-04       Impact factor: 3.851

4.  A and B blood group antigen expression on mixed colony cells and erythroid precursors: relevance for human allogeneic bone marrow transplantation.

Authors:  H A Blacklock; F Katz; R Michalevicz; G R Hazlehurst; L Davies; H G Prentice; A V Hoffbrand
Journal:  Br J Haematol       Date:  1984-10       Impact factor: 6.998

5.  Marrow transplant for acute nonlymphoblastic leukemia in first remission: a follow-up.

Authors:  E D Thomas; F Hutchinson
Journal:  N Engl J Med       Date:  1983-06-23       Impact factor: 91.245

6.  Engraftment and transfusion requirements after allogeneic marrow transplantation for patients with acute non-lymphocytic leukemia in first complete remission.

Authors:  W Bensinger; F B Petersen; M Banaji; C D Buckner; R Clift; S J Slichter; R Storb; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1989-07       Impact factor: 5.483

7.  Variables predicting bacterial and fungal infections after allogeneic marrow engraftment.

Authors:  T Paulin; O Ringdén; B Nilsson; B Lönnqvist; G Gahrton
Journal:  Transplantation       Date:  1987-03       Impact factor: 4.939

8.  Erythrocyte depletion of ABO-incompatible bone marrow.

Authors:  I Sniecinski; S Henry; B Ritchey; D R Branch; K G Blume
Journal:  J Clin Apher       Date:  1985       Impact factor: 2.821

9.  ABO blood group system and bone marrow transplantation.

Authors:  R P Gale; S Feig; W Ho; P Falk; C Rippee; R Sparkes
Journal:  Blood       Date:  1977-08       Impact factor: 22.113

Review 10.  Transfusion problems associated with transplantation.

Authors:  R Storb; P L Weiden
Journal:  Semin Hematol       Date:  1981-04       Impact factor: 3.851

View more
  5 in total

1.  Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants.

Authors:  Melhem Solh; Claudio Brunstein; Shanna Morgan; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-14       Impact factor: 5.742

Review 2.  Clinical use of rHuEPO in bone marrow transplantation.

Authors:  S Klaesson
Journal:  Med Oncol       Date:  1999-04       Impact factor: 3.064

Review 3.  Recombinant erythropoietin in clinical practice.

Authors:  T Ng; G Marx; T Littlewood; I Macdougall
Journal:  Postgrad Med J       Date:  2003-07       Impact factor: 2.401

4.  Recommendations on RBC Transfusion Support in Children With Hematologic and Oncologic Diagnoses From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative.

Authors:  Marie E Steiner; Nicole D Zantek; Simon J Stanworth; Robert I Parker; Stacey L Valentine; Leslie E Lehmann; Cassandra D Josephson; Scot T Bateman; Naomi L C Luban
Journal:  Pediatr Crit Care Med       Date:  2018-09       Impact factor: 3.624

5.  Significance of donor-derived isoagglutinins in ABO-Incompatible hematopoietic stem cell transplantation.

Authors:  Hee-Jung Chung; Je-Hwan Lee; Seog-Woon Kwon
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.